Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 484

Sort by

Sort Order Select

Journal Articles

Molecular and Expression Characterization of Monosomy 7 and Del(7q)

Vera Adema, PhD, Cassandra M Kerr, MS, Hassan Awada, MD, Sunisa Kongkiatkamon, MD, Bhumika J. Patel, MD, Mikkael A. Sekeres, MD MS, Valeria Visconte, PhD, John Barnard, Jaroslaw P. Maciejewski, MD PhD, Torsten Haferlach, MD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-142507

Published: 2020

Journal Articles

Double Genetic Hits and Subclonal Mosaicism in the Ras Signaling Pathway in Myeloid Neoplasia

Sunisa Kongkiatkamon, MD, Yasunobu Nagata, MD PhD, Vera Adema, PhD, Hassan Awada, MD, Misam Zawit, MD, Laila Terkawi, Simona Pagliuca, MD, Carmelo Gurnari, MD, Cassandra M Kerr, MS, Mikkael A. Sekeres, MD MS, Hetty E. Carraway, MD MBA, Yogenthiran Saunthararajah, MD, Bhumika J. Patel, MD, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-143210

Published: 2020

Journal Articles

The Genomic Landscape of Wilms' Tumor 1 ( WT1 ) Mutant Acute Myeloid Leukemia

Hassan Awada, MD, Arda Durmaz, Carmelo Gurnari, MD, Misam Zawit, MBBS, Sunisa Kongkiatkamon, MD, Simona Pagliuca, MD, Cassandra M. Kerr, MS, Hetty E. Carraway, MD MBA, Aziz Nazha, MD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-139920

Published: 2020

Journal Articles

A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia

Aziz Nazha, MD, Sudipto Mukherjee, MD PhD MPH, Caitlin Siebenaller, PharmD, Madeline Waldron, PharmD, BCOP, Eric Parsons, RN, Jenna Thomas, Hetty E. Carraway, MD MBA, Dale Grabowski, BS, Yihong Guan, PhD, Aaron T. Gerds, MDMS, Bhumika J. Patel, MD, Anjali S Advani, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-139494

Published: 2020

Journal Articles

TET2 Inhibitory Effects of Eltrombopag Contribute Its Hematopoietic Activity

Yihong Guan, PhD, Metis Hasipek, PhD, Bhumika J. Patel, MD, Dale Grabowski, BS, Anand D. Tiwari, PhD, Sunisa Kongkiatkamon, MD, Cassandra M Kerr, MS, Aziz Nazha, MD, Yogenthiran Saunthararajah, MD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD, Babal K. Jha, PhD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-142875

Published: 2020

Journal Articles

Type of TP53 Mutations Affects Subclonal Configuration and Selection Pressure for Acquisition of Additional Hits in Contralateral Alleles

Carmelo Gurnari, MD, Vera Adema, PhD, Hassan Awada, MD, Simona Pagliuca, MD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, MD, Thomas Laframboise, PhD, Valeria Visconte, PhD, Maria Teresa Voso, MD, Mikkael A. Sekeres, MD MS, Hetty E. Carraway, MD MBA, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD

Blood (2020) 136 (Supplement 1): 25.

https://doi.org/10.1182/blood-2020-140058

Published: 2020

Journal Articles

The Clonal Trajectories of SF3B1 Mutations in Myeloid Neoplasia

Hassan Awada, MD, Cassandra M. Kerr, MS, Vera Adema, PhD, Carmelo Gurnari, MD, Simona Pagliuca, MD, Heesun J. Rogers, MD PhD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-139528

Published: 2020

Journal Articles

A Phase II Study of CPX-351 As a Novel Therapeutic Approach for Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent Failure

Aziz Nazha, MD, Sudipto Mukherjee, MD PhD MPH, Anjali S Advani, MD, Madeline Waldron, PharmD, BCOP, Caitlin Siebenaller, PharmD, Jenna Thomas, Eric Parsons, RN, Hetty E. Carraway, MD MBA, Aaron T. Gerds, MDMS, Bhumika J. Patel, MD, Mikkael A. Sekeres, MD MS

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-139515

Published: 2020

Journal Articles

Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence

Nathan Radakovich, BA, Luca Malcovati, MD, Manja Meggendorfer, PhD, Mikkael A. Sekeres, MD MS, Jacob Shreve, MD MS, Cameron Beau Hilton, MD, Yazan Rouphail, Wencke Walter, PhD, Stephan Hutter, PhD, Anna Gallì, Sarah Pozzi, Aaron T. Gerds, MDMS, Sudipto Mukherjee, MD PhD MPH, Cassandra M Kerr, MS, Babal K. Jha, PhD, Claudia Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD, Torsten Haferlach, MD, Aziz Nazha, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-140023

Published: 2020

Journal Articles

Personalized Transcriptomic Analyses Identify Unique Signatures That Correlate with Genomic Subtypes in Acute Myeloid Leukemia (AML) Using Explainable Artificial Intelligence

Yazan Rouphail, Nathan Radakovich, BA, Jacob Shreve, MD MS, Sudipto Mukherjee, MD PhD MPH, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-139522

Published: 2020

Journal Articles

Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic

Kimberly C Jenkins, MSNM, Emily C Zabor, DrPH, Lindsey A. R. Mooney, BS, Aaron T. Gerds, MDMS, Kerry O'Hop, BS, Makenzie Guy, BA, Megan Kilbane, MBA, Nathan A Pennell, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-139937

Published: 2020

Journal Articles

Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-140317

Published: 2020

Journal Articles

Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)

Nathan Radakovich, BA, David A. Sallman, MD, Rena J. Buckstein, MD FRCPC, Andrew M. Brunner, MD, Sudipto Mukherjee, MD PhD MPH, Rami Komrokji, MD, Najla Al Ali, M.Sc, Jacob Shreve, MD MS, Yazan Rouphail, Cassandra M Kerr, MS, Yihong Guan, PhD, Teodora Kuzmanovic, BA, Metis Hasipek, PhD, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD

Blood (2020) 136 (Supplement 1): 54–55.

https://doi.org/10.1182/blood-2020-139815

Published: 2020

Journal Articles

Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub

William A. Wood, MD MPH, Donna S. Neuberg, ScD, John Colton Thompson, Martin S. Tallman, MD, Mikkael A. Sekeres, MD MS, Laurie H. Sehn, MDMPH, Kenneth Anderson, MD, Aaron D Goldberg, MDPhD, Nathan A Pennell, MD PhD, Charlotte M. Niemeyer, MD, Emily Tucker, MS, Kathleen Hewitt, DNP,CPHQ,AACC,RN, Robert M Plovnick, MD MS, Lisa K. Hicks, MD MSc

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141327

Published: 2020

Journal Articles

Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents?

Blood (2019) 134 (Supplement_1): 1270.

https://doi.org/10.1182/blood-2019-128967

Published: 2019

Journal Articles

TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia

Yihong Guan, PhD, Anand D. Tiwari, PhD, James G Phillips, PhD, Metis Hasipek, PhD, Dale Grabowski, BS, Cassandra M Kerr, MS, Vera Adema, PhD, Yasunobu Nagata, MD PhD, Valeria Visconte, PhD, Tomas Radivoyevitch, PhD, Daniel Lindner, MD PhD, Manja Meggendorfer, PhD, Mohamed Abazeed, Mikkael A. Sekeres, MD MS, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD, Babal K. Jha, PhD

Blood (2019) 134 (Supplement_1): 880.

https://doi.org/10.1182/blood-2019-131920

Published: 2019

Journal Articles

Therapeutic Applications of a Unique Calcium Channel Blocker to Target SF3B1 MDS

Sunisa Kongkiatkamon, Anand Tiwari, Vera Adema, PhD, Cassandra M Kerr, MS, Bartlomiej Przychodzen, Hassan Awada, Jibran Durrani, Yvonne Parker, Drew Adams, Yuriy Fedorov, Hetty E. Carraway, MD MBA, Chao-Yie Yang, Mikkael A. Sekeres, MD MS, Daniel J. Lindner, James G Phillips, PhD, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD

Blood (2019) 134 (Supplement_1): 881.

https://doi.org/10.1182/blood-2019-128671

Published: 2019

Journal Articles

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Tracy I. George, MD, Christopher R. Cogle, MD, Guillermo Garcia-Manero, MD, David L. Grinblatt, Rami Komrokji, Michael R. Savona, MD, Bart L. Scott, MD, Mikkael A. Sekeres, MD MS, David P. Steensma, MD, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Melissa Nifenecker, Arlene S. Swern, Kathryn Foucar

Blood (2019) 134 (Supplement_1): 4747.

https://doi.org/10.1182/blood-2019-122913

Published: 2019

Journal Articles

Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes

Blood (2019) 134 (Supplement_1): 1715.

https://doi.org/10.1182/blood-2019-129141

Published: 2019

Journal Articles

How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS

Yasunobu Nagata, MD PhD, Ran Zhao, Hassan Awada, Cassandra M Kerr, MS, Abhinav Goyal, Inom Mirzaev, Sunisa Kongkiatkamon, Aziz Nazha, MD, Tomas Radivoyevitch, PhD, Jacob Scott, MD, Mikkael A. Sekeres, MD MS, Brian P. Hobbs, PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 1716.

https://doi.org/10.1182/blood-2019-127285

Published: 2019

NARROW

Molecular and Expression Characterization of Monosomy 7 and Del(7q)

Double Genetic Hits and Subclonal Mosaicism in the Ras Signaling Pathway in Myeloid Neoplasia

The Genomic Landscape of Wilms' Tumor 1 ( WT1 ) Mutant Acute Myeloid Leukemia

A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia

TET2 Inhibitory Effects of Eltrombopag Contribute Its Hematopoietic Activity

Type of TP53 Mutations Affects Subclonal Configuration and Selection Pressure for Acquisition of Additional Hits in Contralateral Alleles

The Clonal Trajectories of SF3B1 Mutations in Myeloid Neoplasia

A Phase II Study of CPX-351 As a Novel Therapeutic Approach for Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent Failure

Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence

Personalized Transcriptomic Analyses Identify Unique Signatures That Correlate with Genomic Subtypes in Acute Myeloid Leukemia (AML) Using Explainable Artificial Intelligence

Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic

Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS

Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)

Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub

Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents?

TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia

Therapeutic Applications of a Unique Calcium Channel Blocker to Target SF3B1 MDS

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes

How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only